LinkOPH

MILAN — A phase 2a clinical trial will evaluate the safety, tolerability and efficacy of an intracameral implant for sustained delivery of a prostaglandin formulation in patients with ocular hypertension or early glaucoma. ENV515 (Envisia Therapeutics) is made of a biodegradable polymer containing travoprost and has successfully undergone preclinical studies, showing sustained IOP lowering efficacy for up to 8 months after a single dose, Jay S. Pepose, MD, PhD, said at the annual joint meeting of Ocular Surgery News and the Italian Ophthalmological Society.

Read more →

THOROFARE, N.J. — Healio.com, the online portal of The Wyanoke Group and SLACK Incorporated, has been named winner of the 2014 North American Sitecore Experience Awards in the category of “The ROI Award.”The award recognizes companies who have leveraged global software company Sitecore’s technology to develop websites that deliver outstanding user experiences.

Read more →

I strongly believe access to compounded pharmaceutical products is critically important for the ophthalmologist and especially for patients. This is currently an area in flux with significant controversy, and many parties have significant vested interests. The following thoughts are my own, and I would like to disclose that in one form or another, I consult for every level of pharmaceutical product distribution I will discuss in this commentary. When I am sorting out my own personal conflicts of interest, I simply return to a “patient first” prioritization, and it is (Read more...)

Nothing makes me crankier than seeing a promising medical technology or treatment held hostage by a bad business plan. As an aside, nothing I write produces more agita in my editors than when I propose to vent my spleen on topics such as this. I find it even more distressing when cool stuff is marketed primarily on the financial benefits a test or treatment will bring to the practice that adopts the new technology. This is especially depressing when the technology is not only cool in its own right, but (Read more...)

A 62-year-old white man was referred to the retina clinic for evaluation of rapid decreased vision of his left eye occurring 5 days before presentation.The patient reported noticing a dark area of his vision in his left eye while he was watching television. He denied any eye pain. A review of systems was negative for fevers, chills, weight loss, night sweats, jaw claudication, scalp tenderness, diplopia and myalgias. He was seen by an outside ophthalmologist who started him on oral prednisone and timolol in the left eye for reasons that (Read more...)